Opus Genetics, Inc.

What they do

Opus Genetics develops durable, one-time gene therapies delivered by subretinal injection to address the genetic causes of inherited retinal diseases such as LCA5-related mutations, BEST1-related retinal degeneration, and retinitis pigmentosa. Its pipeline includes seven AAV-based programs (OPGx-LCA5, OPGx-BEST1, OPGx-RHO, OPGx-CNGB1, OPGx-RDH12, OPGx-NMNAT1, and OPGx-MERTK) plus Phentolamine Ophthalmic Solution 0.75%, which is FDA-approved for pharmacologically induced mydriasis. The company was founded as Ocuphire Pharma in 2018 and acquired private Opus Genetics in October 2024. Programs draw on science from the University of Pennsylvania, Harvard Medical School, and the University of Florida.

Revenue drivers

• License and collaborations revenue — Quarterly revenue was $0.8 million for the quarter ended June 30, 2026, versus $2.9 million in the prior-year quarter, driven by licensing and collaboration arrangements rather than product sales.
• Phentolamine Ophthalmic Solution 0.75% — An FDA-approved small-molecule therapy for pharmacologically induced mydriasis, with additional potential indications in presbyopia and low-light visual disturbances after keratorefractive surgery; the company states it does not yet have sales or marketing infrastructure in place.
• Gene therapy pipeline (pre-revenue) — Seven AAV-based programs, led by OPGx-LCA5 and OPGx-BEST1, are in clinical or preclinical development and have not generated product revenue; OPGx-LCA5 has received FDA Rare Pediatric Disease, RMAT, and Orphan Drug designations and a grant from the FDA Office of Orphan Drug Products.
• Viatris collaboration — The 10-Q references continued drug development and commercialization under an agreement with Viatris, Inc. as part of forward-looking statements; no separate revenue figure was broken out in the excerpts provided.

Recent performance

Second quarter 2026 revenue was $0.8 million, down from $2.9 million in the prior-year quarter. Annual revenue declined from $39.9 million in 2022 to $11.0 million in 2024, then rose to $14.2 million in 2025; recent quarterly revenue fell from $3.9 million in Q4 2025 to $2.2 million in Q1 2026 and $755,000 in Q2 2026. Net losses were $57.5 million in 2024 and $49.6 million in 2025. Operating cash flow was negative $35.3 million in 2025. As of June 30, 2026, cash and equivalents were $88.8 million against total liabilities of $106.0 million and shareholder equity of negative $13.0 million.

Strategy

Opus Genetics is advancing five gene therapy programs, with OPGx-BEST1 Cohort 1 topline data targeted for the second week of September 2026 and four additional clinical readouts expected in 2027. Enrollment is complete in the OPGx-LCA5 registrational Phase 3 trial (eight participants, six-month run-in, both-eye treatment), with dosing expected in Q4 2026 and topline data by the end of 2027. OPGx-RDH12 is expected to enter the clinic in Q4 2026, OPGx-MERTK at Cleveland Clinic Abu Dhabi in Q1 2027, and OPGx-RHO globally in the second half of 2027. Management states the cash runway into 2029 is intended to fund multiple clinical inflection points and pursue potential Priority Review Voucher opportunities.

Risks

• Novel technology and regulatory uncertainty — The company states its gene therapy candidates are based on novel technology that is difficult to develop and manufacture, which may cause delays and difficulties in obtaining regulatory approval for programs such as OPGx-BEST1 and OPGx-LCA5.
• Reliance on a single pipeline — The 10-K risk factors state the company depends heavily on the success of its product pipeline, and failure to find strategic partners or adequately develop or commercialize pipeline products would materially harm the business.
• No significant product revenue and ongoing losses — The 10-Q risk factors state the company has not generated significant revenue from sales of any products and expects to incur losses for the foreseeable future, with operating cash flow of negative $35.3 million in 2025.
• Capital needs and dilution — The company states it needs substantial additional capital, its future viability is difficult to assess given a short operating history, and raising additional capital may cause stockholder dilution; it depends on third parties for trials and manufacturing.

Outlook

Management expects OPGx-BEST1 Cohort 1 3-month topline data in the second week of September 2026 and OPGx-LCA5 dosing to begin in Q4 2026, with LCA5 topline data by the end of 2027. Four additional clinical readouts are expected in 2027 across the RDH12, MERTK, and RHO programs. The company states current cash and potential future fundings under the Oberland Capital note purchase agreement should fund operations into 2029, excluding callable warrant proceeds and future milestones.